Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Computer Program Assesses Alzheimer's Risk

By HospiMedica staff writers
Posted on 29 Jun 2005
Scientists have devised a brain scan-based computer program that rapidly and effectively measures metabolic activity in a major area of the brain affected in the early stages of Alzheimer's disease (AD). More...


Utilizing the program, the researchers established that decreases in brain metabolism in healthy people were linked with the later development of the debilitating disorder, AD, according to a new study.

"This is the first demonstration that reduced metabolic activity in the hippocampus may be used to help predict future Alzheimer's disease,” said Lisa Mosconi, Ph.D., a research scientist in the department of psychiatry, New York University School of Medicine (NYU, NY, USA), who developed the computer program and was the principal investigator of the study.

The computer program consists of an image analysis method that allows researchers to standardize and computer automate the sampling of positron emission tomography (PET) brain scans. The NYU scientists hope the method will enable clinicians to measure the metabolic rate of the hippocampus and identify lower-than-normal metabolic activity.

HipMask uses magnetic resonance imaging (MRI) to anatomically probe the PET scan. MRI was utilized to determine the total volume of the hippocampus and then to define that portion (in particular the HipMask) that was shared by all subjects, regardless of their disease status. The HipMask was applied to PET scans to obtain estimates of the hippocampal glucose metabolism.

The researchers followed 53 healthy individuals between the ages of 54 and 80 for at least nine years, and in some cases for as long as 24 years. All subjects received two flurodeoxyglucose (FDG)-PET scans--one at baseline and a follow-up after three years. Thirty individuals had a second follow-up scan after an additional seven years. In total, there were 136 PET scans.

The investigators utilized the HipMask for all 136 scans. The findings demonstrated that hippocampal glucose metabolism, as determined by the HipMask, was considerably reduced from 15% to 40% on the first scan, compared to controls, of those 25 subjects who would later experience cognitive decline related to either mild cognitive impairment or to AD. The investigators discovered that the baseline hippocampal glucose metabolism was the only brain or clinical assessment that forecasted future cognitive decline.




Related Links:
New York University School of Medicine

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.